Versago Vascular Access Inc., a West Bridgewater, Mass.-based developer of a “reverse needle” subcutaneous access port, raised $1.65m in seed funding.
Backers included Primo Medical Group‘s network of individual and institutional investors.
The company intends to use the funds to further develop its line of port technology, initiate regulatory review and conduct animal testing.
Led by Andrea Patisteas, CEO and Co-Founder, Versago Vascular Access has designed and developed a new subcutaneous port to access the body’s bloodstream and anatomical cavities that collect serous or ascitic fluid.
The technology provides a large bore, reusable, power injectable conduit directly into a patient’s bloodstream or other anatomical areas and in certain applications could potentially replace current technologies like ports, peripherally inserted central catheters (PICC) and central venous catheters (CVC) for a myriad of procedures.
The company is a spinoff of Primo Medical Group, a manufacturer of medical devices and precision machined components.